Achillion (ACHN) Enters 6.4M Direct Offering at $6.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Join SI Premium – FREE
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced today that it has entered into a definitive agreement with funds managed by QVT Financial LP for the sale of 6,367,853 shares of its common stock.
The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in gross proceeds to Achillion, before deducting estimated offering expenses, of approximately $41.8 million. The sale and issuance of the shares is expected to close on or about September 4, 2012, subject to customary closing conditions.
The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in gross proceeds to Achillion, before deducting estimated offering expenses, of approximately $41.8 million. The sale and issuance of the shares is expected to close on or about September 4, 2012, subject to customary closing conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QVT raises concerns about Jackson Financial subsidiary solvency
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Rivian names Derek Mulvey as interim CFO effective Oct. 30
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
QVT FinancialSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
